Literature DB >> 7638741

Antitumor activity of three mouse mammary cancer cell lines after interferon-gamma gene transfection.

Y L Matory1, M Chen, D M Dorfman, A Williams, P S Goedegebuure, T J Eberlein.   

Abstract

BACKGROUND: The antitumor effects of three mouse mammary tumors transfected to express interferon-gamma were evaluated.
METHODS: Three immunologically different tumors were used: DA3, EMT6, and 410. All three cell lines were successfully transfected with highly efficient viral vectors. Wild type or transfected tumor cells were injected subcutaneously into Balb/c mice. Animals were observed for tumor growth and the induction of immunologic memory.
RESULTS: A significant decrease occurred in the size of all transfected tumors, EMT6 1.9 cm2, DA3 1.7, and 410 1.8 compared with nontransfected control tumors with a mean size of 4 cm2 on day 30. To further test the development of immunity, animals were injected with either nontransfected or transfected tumors and challenged with nontransfected tumor. Animals immunized with transfected tumor cells had significantly smaller tumors, EMT6 2.5 cm2, DA3 3.1, and 410 2.4 compared with controls with a mean size of 4 cm2. No specific splenocyte cytotoxicity was shown. Expression of major histocompatibility complex class I antigens was enhanced in the 410 and DA3 tumor lines.
CONCLUSIONS: Significant antitumor effects were observed after interferon-gamma gene transfection of three mouse mammary cancer cell lines. Up-regulation of major histocompatibility complex class I antigen expression is a partial explanation of these findings. These results provide preliminary studies for gene therapy of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638741     DOI: 10.1016/s0039-6060(05)80331-9

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

1.  HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.

Authors:  M Feinmesser; A Sulkes; S Morgenstern; J Sulkes; S Stern; E Okon
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.

Authors:  Vy Phan-Lai; Forrest M Kievit; Stephen J Florczyk; Kui Wang; Mary L Disis; Miqin Zhang
Journal:  Anticancer Agents Med Chem       Date:  2014-02       Impact factor: 2.505

Review 3.  The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors.

Authors:  P S Goedegebuure; T J Eberlein
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

Review 4.  Gene therapy for carcinoma of the breast: Genetic immunotherapy.

Authors:  T V Strong
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.